Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
336 participants
INTERVENTIONAL
2000-04-30
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
NCT00549874
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
NCT00551564
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
NCT00116831
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
NCT00499707
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
NCT00318656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosiglitazone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Tempe, Arizona, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Redwood City, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Santa Barbara, California, United States
GSK Investigational Site
Tustin, California, United States
GSK Investigational Site
Ukiah, California, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
New Britain, Connecticut, United States
GSK Investigational Site
Norwalk, Connecticut, United States
GSK Investigational Site
Newark, Delaware, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Winter Park, Florida, United States
GSK Investigational Site
Blue Ridge, Georgia, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Peoria, Illinois, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
South Bend, Indiana, United States
GSK Investigational Site
Slidell, Louisiana, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Springfield, Massachusetts, United States
GSK Investigational Site
Royal Oak, Michigan, United States
GSK Investigational Site
Brooklyn Center, Minnesota, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Henderson, Nevada, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Albany, New York, United States
GSK Investigational Site
Binghamton, New York, United States
GSK Investigational Site
Endwell, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Hermitage, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Columbia, South Carolina, United States
GSK Investigational Site
Beaumont, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Edmonds, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Madison, Wisconsin, United States
GSK Investigational Site
Milwaukee, Wisconsin, United States
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
North Bay, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Peterborough, Ontario, Canada
GSK Investigational Site
Smiths Falls, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Laval, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Viña del Mar, Región de Valparaíso, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Königsfeld im Schwarzwald, Baden-Wurttemberg, Germany
GSK Investigational Site
Unterschneidheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Grafing, Bavaria, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Borna, Saxony, Germany
GSK Investigational Site
Delitzsch, Saxony, Germany
GSK Investigational Site
Dresden, Saxony, Germany
GSK Investigational Site
Görlitz, Saxony, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Apolda, Thuringia, Germany
GSK Investigational Site
Jelgava, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Talsi, , Latvia
GSK Investigational Site
Valmiera, , Latvia
GSK Investigational Site
Durango, Durango, Mexico
GSK Investigational Site
Guadalajara, Jalisco, Mexico
GSK Investigational Site
México, , Mexico
GSK Investigational Site
Amersfoort, , Netherlands
GSK Investigational Site
Leiden, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Zwaag, , Netherlands
GSK Investigational Site
Banská Bystrica, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Martin, , Slovakia
GSK Investigational Site
Alicante, , Spain
GSK Investigational Site
Granada, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Sagunto/Valencia, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
GSK Investigational Site
Liverpool, Merseyside, United Kingdom
GSK Investigational Site
Edinburgh, Midlothian, United Kingdom
GSK Investigational Site
Paisley, Renfrewshire, United Kingdom
GSK Investigational Site
Bath, Somerset, United Kingdom
GSK Investigational Site
Livingston, West Lothian, United Kingdom
GSK Investigational Site
Gateshead, , United Kingdom
GSK Investigational Site
Newport, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bakris GL, Ruilope LM, Weston WM, Porter LE, Huang C, Heise MA, Freed MI. Rosiglitazone (RSG) added to metformin (MET) reduces urinary albumin/creatinine ratio and ambulatory blood pressure in subjects with microalbuminuria and type 2 diabetes (T2DM). Diabetes 2005;54(suppl 1):A134. Poster (543-P) presented at 65th Scientific Sessions of the Amercian Diabetes Association, June 10-14, 2005, San Diego, California.
Ruilope LM, Bakris GL, McMorn SO, Weston WM, Huang C, Heise MA, Porter LE, Freed MI. Rosiglitazone added to metformin reduces urinary albumin/creatinine ratio and ambulatory blood pressure in subjects with microalbuminuria and type 2 diabetes. Diabetologia 2005;48(suppl 1):A283. Poster (779) presented at the 41st Annual Meeting of the European Association for the Study of Diabetes, September 12-15, 2005, Athens, Greece.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRL-49653/137
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.